Idiopathic Pulmonary Fibrosis clinical trials at UCSD

2 in progress, 1 open to eligible people

Showing trials for

  • Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

    open to eligible people ages 40 years and up

    The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com

    San Diego, California and other locations

  • Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

    Sorry, in progress, not accepting new patients

    Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.

    La Jolla, California and other locations

Last updated: